Evidence map›Paper›PMID 40289600›Full record

ArticleFuture oncology (London, England)2025

Prognostic factors of long-term response to androgen receptor signaling inhibitors used as first-line treatment for mCRPC.

Antonello Veccia, Umberto Basso, Carlo Cattrini, Paola Ermacora, Marco Maruzzo, Martina Alberti, Cecilia Anesi, Davide Bimbatti, Massimiliano Cani, Veronica Crespi and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Antonello VecciaMedical Oncology, Santa Chiara Hospital, Trento, Italy.
Umberto BassoOncology Unit 1, Istituto Oncologico Veneto - IOV IRCCS, Padova, Italy.
Carlo Cattrini"Maggiore della Carità", University Hospital, Novara, Italy.
Paola ErmacoraDepartment of Oncology, Santa Maria della Misericordia Academic Hospital, Udine, Italy.
Marco MaruzzoOncology Unit 1, Istituto Oncologico Veneto - IOV IRCCS, Padova, Italy.
Martina AlbertiDepartment of Oncology, Santa Maria della Misericordia Academic Hospital, Udine, Italy.
Cecilia AnesiMedical Oncology, Santa Chiara Hospital, Trento, Italy.
Davide BimbattiOncology Unit 1, Istituto Oncologico Veneto - IOV IRCCS, Padova, Italy.
Massimiliano CaniSan Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.
Veronica CrespiSan Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.
Giovanni FarineaSan Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.
Dzenete KadrijaMedical Oncology, Santa Chiara Hospital, Trento, Italy.
Stefania KinspergherMedical Oncology, Santa Chiara Hospital, Trento, Italy.
Eleonora LaiOncology 3 Unit, Istituto Oncologico Veneto - IOV IRCCS, Padova, Italy.
Ludovica LayDepartment of Oncology, Santa Maria della Misericordia Academic Hospital, Udine, Italy.
Francesca MainesMedical Oncology, Santa Chiara Hospital, Trento, Italy.
Alessia Mennitto"Maggiore della Carità", University Hospital, Novara, Italy.
Francesco PierantoniOncology 3 Unit, Istituto Oncologico Veneto - IOV IRCCS, Padova, Italy.
Alessandro SamuellySan Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.
Susanna UrbanDepartment of Oncology, Santa Maria della Misericordia Academic Hospital, Udine, Italy.
Orazio CaffoMedical Oncology, Santa Chiara Hospital, Trento, Italy.
Consuelo ButtiglieroSan Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAndrogen receptor signaling inhibitors (ARSI) demonstrated to be efficacious as first-line therapy for mCRPC. The present real-world study aimed to identify the characteristics of the long-term responders (LTR) patients to first-line ARSI.

methodsWe retrospectively reviewed a consecutive series of 622 mCRPC patients treated with one ARSI as first line. Patients received standard doses of abiraterone (1000 mg daily plus prednisone 10 mg daily) or enzalutamide (160 mg daily) until progression. Patients with an ARSI exposure ≥ 36 months were considered as LTR.

resultsWe identified 99 LTR patients who were compared to 523 no-LTR patients. At the multivariable analysis, LTR patients showed younger age (

conclusionsSeveral clinical and biological factors allow to identify those patients with higher probability of becoming LTR to ARSI in first-line mCRPC setting.

Indexed as

Androgen Receptor AntagonistsAntineoplastic Combined Chemotherapy ProtocolsProstatic Neoplasms, Castration-ResistantReceptors, AndrogenAgedAged, 80 and overAndrostenesBenzamidesHumansMaleMiddle AgedNitrilesPhenylthiohydantoinPrognosisRetrospective StudiesSignal TransductionabirateroneAndrogen Receptor AntagonistsAndrostenesAR protein, humanBenzamidesenzalutamideNitrilesPhenylthiohydantoinReceptors, Androgenabirateronecastration-resistant prostate cancerenzalutamideLong-term responderprognostic factors

Identifiers

PMID40289600
PMCPMC12140444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.